FI963571A7 - Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi - Google Patents

Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi Download PDF

Info

Publication number
FI963571A7
FI963571A7 FI963571A FI963571A FI963571A7 FI 963571 A7 FI963571 A7 FI 963571A7 FI 963571 A FI963571 A FI 963571A FI 963571 A FI963571 A FI 963571A FI 963571 A7 FI963571 A7 FI 963571A7
Authority
FI
Finland
Prior art keywords
conditions associated
treating conditions
5ht2b receptor
5ht2b
receptor
Prior art date
Application number
FI963571A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963571L (fi
FI963571A0 (fi
Inventor
Jaswant Singh Gidda
Marlene Lois Cohen
James Edmund Audia
Stephen Richard Baker
David Lloyd Garver Nelson
Jesus Ezquerra-Carrera
Carlos Lamas-Peteira
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/380,565 external-priority patent/US5663178A/en
Priority claimed from US08/380,566 external-priority patent/US5688807A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI963571A0 publication Critical patent/FI963571A0/fi
Publication of FI963571L publication Critical patent/FI963571L/fi
Publication of FI963571A7 publication Critical patent/FI963571A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
FI963571A 1994-03-11 1995-03-10 Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi FI963571A7 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21262294A 1994-03-11 1994-03-11
US08/380,565 US5663178A (en) 1995-02-06 1995-02-06 Tetrahydro-beta carbolines
US08/380,566 US5688807A (en) 1994-03-11 1995-02-06 Method for treating 5HT2B receptor related conditions
PCT/US1995/003099 WO1995024200A1 (en) 1994-03-11 1995-03-10 Method for treating 5ht2b receptor related conditions

Publications (3)

Publication Number Publication Date
FI963571A0 FI963571A0 (fi) 1996-09-10
FI963571L FI963571L (fi) 1996-11-08
FI963571A7 true FI963571A7 (fi) 1996-11-08

Family

ID=27395770

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963571A FI963571A7 (fi) 1994-03-11 1995-03-10 Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi

Country Status (11)

Country Link
EP (1) EP0749313A4 (cs)
JP (1) JPH09510216A (cs)
CN (1) CN1148340A (cs)
AU (1) AU679635B2 (cs)
CA (1) CA2185236A1 (cs)
CZ (1) CZ264996A3 (cs)
FI (1) FI963571A7 (cs)
HU (1) HUT75522A (cs)
IL (1) IL112958A0 (cs)
NO (1) NO963785L (cs)
WO (1) WO1995024200A1 (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
AU5317996A (en) * 1995-04-18 1996-11-07 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
GB9523999D0 (en) 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
WO1997035480A1 (en) * 1996-03-15 1997-10-02 Eli Lilly And Company Method of treating common cold or allergic rhinitis
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor
US5886003A (en) * 1996-03-25 1999-03-23 Eli Lilly And Company Methods of treating or ameliorating the symptoms of venomous bites and stings
EA000769B1 (ru) * 1996-03-25 2000-04-24 Эли Лилли Энд Компани Способ лечения при боли, вызванной мигренью
JP2001509130A (ja) * 1996-03-25 2001-07-10 イーライ・リリー・アンド・カンパニー テトラヒドロベータ―カルボリン化合物群
AU4856600A (en) 1999-05-18 2000-12-05 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
IL146564A0 (en) * 1999-05-24 2002-07-25 Mitsubishi Pharma Corp Phenoxypropylamine derivatives and pharmaceutical compositions containing the same
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
GB0203412D0 (en) 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
AU2004237420B2 (en) * 2003-05-09 2009-04-09 Laboratorios Del Dr. Esteve S.A. Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
EP1852129A4 (en) * 2005-02-08 2009-07-15 Astellas Pharma Inc REMEDIES FOR IRRITATION SYNDROME
ES2371106T3 (es) 2005-08-08 2011-12-27 Astellas Pharma Inc. Derivado de acilguanidina o sal del mismo.
EP1988075B1 (en) * 2006-02-20 2012-01-25 Astellas Pharma Inc. Pyrrole derivative or salt thereof
EP2280968A2 (en) 2008-03-24 2011-02-09 Medivation Technologies, Inc. Pyrido [3, 4-b]indoles and methods of use
MX2011005221A (es) 2008-11-21 2011-08-03 Raqualia Pharma Inc Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b.
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
EP2480080A4 (en) * 2009-09-23 2014-01-08 Medivation Technologies Inc PYRIDO [3,4-B] INDOLES AND METHODS OF USE
JP5791611B2 (ja) * 2009-09-23 2015-10-07 メディベイション テクノロジーズ， インコーポレイテッド ピリド［３，４−ｂ］インドールおよび使用方法
AU2017242027B2 (en) 2016-04-01 2020-10-08 Recurium Ip Holdings, Llc Estrogen receptor modulators
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
JP7636796B2 (ja) * 2019-02-27 2025-02-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
BR112022002138A2 (pt) 2019-08-06 2022-04-19 Recurium Ip Holdings Llc Moduladores do receptor de estrogênio para tratamento de mutantes
US11759452B2 (en) 2020-05-08 2023-09-19 Psilera Inc. Compositions of matter and pharmaceutical compositions
EP4208445A4 (en) * 2020-09-01 2024-10-02 Enveric Biosciences Canada Inc. Halogenated psilocybin derivatives and methods of using
EP4384172A4 (en) 2021-08-12 2025-07-30 Kuleon Llc HALLUCINOGENIC AND NON-HALLUCINOGENIC SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
WO2023143393A1 (zh) * 2022-01-29 2023-08-03 上海科技大学 三并环类化合物、其制备方法和用途
WO2025137581A1 (en) * 2023-12-21 2025-06-26 Atai Therapeutics, Inc. Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492304A (en) * 1968-06-24 1970-01-27 Warner Lambert Pharmaceutical 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones
DE3240514A1 (de) * 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4520024A (en) * 1983-02-11 1985-05-28 Eli Lilly And Company Method of selectively blocking peripheral vascular serotonergic receptors
EP0620222A3 (en) * 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole

Also Published As

Publication number Publication date
AU2118695A (en) 1995-09-25
EP0749313A4 (en) 2001-10-24
EP0749313A1 (en) 1996-12-27
CZ264996A3 (cs) 1998-01-14
IL112958A0 (en) 1995-06-29
HUT75522A (en) 1997-05-28
FI963571L (fi) 1996-11-08
CA2185236A1 (en) 1995-09-14
JPH09510216A (ja) 1997-10-14
CN1148340A (zh) 1997-04-23
NO963785D0 (no) 1996-09-10
WO1995024200A1 (en) 1995-09-14
FI963571A0 (fi) 1996-09-10
AU679635B2 (en) 1997-07-03
NO963785L (no) 1996-11-01
HU9602482D0 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
FI963571L (fi) Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi
FI954863A0 (fi) Parannettu menetelmä polymeerien muodostamiseksi
FI940487A7 (fi) Vianmääritysmenetelmä kehitysprosessia varten
DE69534965D1 (de) Abscheidungsverfahren
FI953209A7 (fi) Menetelmä kutsutun tilaajan tavoittamiseksi
FI972318A0 (fi) Menetelmä ikkunan irrottamiseksi
FI962069L (fi) Menetelmä karpolaktaamin valmistamiseksi
FI971568A7 (fi) Menetelmä resistenttien kasvainten hoitamiseksi
EP0669362A3 (en) Process for the preparation of polytitanosiloxanes soluble in organic solvents.
DE69520558D1 (de) Halogenierungsverfahren
KR970001365A (ko) 알킬하이드로겐클로로실란의 제조방법
FI20050181L (fi) Menetelmä valmistaa 21-kloorikortikosteroideja
ZA952022B (en) Method for treating 5HT2B receptor related conditions
DE69703305D1 (de) System zum herstellen von polsterelementen
FI955800L (fi) Menetelmä aminoalkyyliganidiinien valmistamiseksi
FI944583L (fi) Menetelmä hissin käynnistämiseksi
FI964001L (fi) Menetelmä 7-trialkyylisilyylibakkatiini III:n valmistamiseksi
DE69507032D1 (de) Chlorhydrin-verfahren
EP0669428A3 (en) Method of laying roads.
IT1275140B (it) Gruppo fanale-proiettore per veicoli
FI963018A7 (fi) Menetelmä gammapyronien valmistamiseksi
FI971675A7 (fi) Menetelmä bradykiniinin liittyvien tilojen inhiboimiseksi
FI955856A0 (fi) Menetelmä sokereiden dekarbonyloimiseksi
FI956215A7 (fi) Menetelmä 5H-dibentso-(b,f)-atsepiinin puhdistamiseksi
FI962626L (fi) Menetelmä hiokkeen valmistusprosessin ohjaamiseksi